

Luxembourg, 11.11.2020

# Public

## **Environmental and Social Data Sheet**

Project Name:	COVID-19 ESSENTIAL API MANUFACTURING IN AFRICA
Project Number:	2020-0584
Country:	REGIONAL - AFRICA
Project Description:	The operation aims at increasing the local manufacturing capacity of Active Pharmaceutical Ingredients (APIs) in Sub-Saharan Africa (SSA).
EIA required:	no
Project included in Carbon For	otprint Exercise: no

## **Environmental and Social Assessment**

#### **Environmental Assessment**

**Overview** 

The proposed envelope covers different sub-operations that will be carried out in order to support the expansion of the pharmaceutical manufacturing capacity in the Sub-Saharan Africa region, notably regarding Active Pharmaceutical Ingredients.

The overall environmental impact and the residual environmental risks of the operation are unknown at this stage and will be assessed at the appraisal of the individual sub-operations. If located in the EU, production of pharmaceutical products would fall under Annex II of the EIA Directive 2014/52/EU amending the Directive 2011/92/EU. For each sub-operation under this envelope, a full environmental appraisal will be undertaken at time of allocation, taking into account the corresponding national environmental law and the relevant ESIA process together with the potential application of industrial accident prevention legislation as well as the sub-operation's risk to climate change.

#### **Social Assessment**

Access to pharmaceuticals is one of the most cost-effective ways to ensure long and healthy lives. If successful, the operation is expected to lead to important societal benefits, addressing inequalities within and among nations with regards to access of effective drugs, especially at the time of crisis (such as COVID-19), primarily by reducing dependency on imports of pharmaceuticals and their raw materials.

Through the expansion of manufacturing activities is the SSA region, the operation is also expected to contribute to the development of the local and regional pharmaceutical industry, and to provide employment opportunities for skilled and unskilled workforce.



Luxembourg, 11.11.2020

## **Conclusions and Recommendations**

During the appraisal of sub-operations, the Environmental & Social impact as well as the processes and procedures of individual beneficiaries will be assessed. The Bank will require the promoters to ensure that implementation of the sub-projects will be done in accordance with the Bank's environmental and social policy and standards.

Under these conditions, the operation is considered acceptable for EIB financing in E&S terms.